Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
The present study clarified a novel biomarker anti-CD300e antibody to diagnose fulminant type 1 diabetes (FT1D). Seromic analysis revealed 9 antibodies which showed high signals in sera from patients with FT1D in acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in acute phase than that in autoimmune type 1 diabetes (T1AD), type 2 diabetes (T2D), autoimmune thyroid disease (AITD) patients and healthy controls (HC) by ELISA.
|